$235.40
-0.19-0.08%
Last update: 10:33 AM
15 minutes delayed
Comments
Loading...
Alnylam Pharmaceuticals
ALNYNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Analyst Ratings, Price Targets, Forecasts
Alnylam Pharmaceuticals Inc has a consensus price target of $255.28 based on the ratings of 27 analysts. The high is $400 issued by HC Wainwright & Co. on June 24, 2024. The low is $159 issued by Leerink Partners on June 25, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Morgan Stanley, and Canaccord Genuity on July 22, 2024, July 12, 2024, and July 8, 2024, respectively. With an average price target of $277.33 between Cantor Fitzgerald, Morgan Stanley, and Canaccord Genuity, there's an implied 17.81% upside for Alnylam Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Morgan Stanley
Canaccord Genuity
JP Morgan
UBS
1calculated from analyst ratings
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | -6.54% | Cantor Fitzgerald | Olivia Brayer | $150 → $220 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | 8.33% | Morgan Stanley | Michael Ulz | $250 → $255 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 51.66% | Canaccord Genuity | Whitney Ijem | $283 → $357 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | 5.35% | JP Morgan | Jessica Fye | $160 → $248 | Maintains | Neutral | Get Alert |
| 07/01/2024 | Buy Now | -36.28% | Cantor Fitzgerald | Olivia Brayer | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 06/28/2024 | Buy Now | 22.34% | UBS | Eliana Merle | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 12.57% | RBC Capital | Luca Issi | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 25.32% | Stifel | Paul Matteis | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 23.62% | Citigroup | David Lebovitz | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 25.32% | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -32.46% | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | 19.8% | TD Cowen | Ritu Baral | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 10.45% | Evercore ISI Group | Liisa Bayko | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | 23.62% | Barclays | Gena Wang | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | 6.2% | RBC Capital | Luca Issi | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -12.06% | Wells Fargo | Tiago Fauth | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | 6.2% | Morgan Stanley | Michael Ulz | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 16.82% | Needham | Joseph Stringer | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 69.92% | HC Wainwright & Co. | Patrick Trucchio | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | -0.59% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 20.22% | Canaccord Genuity | Whitney Ijem | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 69.92% | HC Wainwright & Co. | Patrick Trucchio | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -4.42% | Chardan Capital | Keay Nakae | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -15.04% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | -0.59% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 67.8% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -36.28% | Cantor Fitzgerald | Olivia Brayer | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | -0.17% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/20/2024 | Buy Now | -0.17% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -31.61% | Wells Fargo | Tiago Fauth | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | -3.57% | Citigroup | David Lebovitz | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -0.17% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -4.42% | Chardan Capital | Keay Nakae | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -26.51% | Goldman Sachs | Salveen Richter | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
| 02/15/2024 | Buy Now | -15.04% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 02/14/2024 | Buy Now | -0.17% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/13/2024 | Buy Now | -25.23% | Morgan Stanley | Michael Ulz | $184 → $176 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/01/2024 | Buy Now | -27.78% | JP Morgan | Jessica Fung | $150 → $170 | Maintains | Neutral | Get Alert |
| 01/22/2024 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/18/2024 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/15/2023 | Buy Now | 67.8% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | -29.91% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/14/2023 | Buy Now | -7.82% | Piper Sandler | Edward Tenthoff | $210 → $217 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | -27.36% | Wells Fargo | Tiago Fauth | → $171 | Initiates | → Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | 67.8% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -2.29% | RBC Capital | Luca Issi | $235 → $230 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -22.26% | Morgan Stanley | Michael Ulz | $175 → $183 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | -27.78% | Cantor Fitzgerald | Olivia Brayer | $190 → $170 | Maintains | Neutral | Get Alert |
| 10/11/2023 | Buy Now | — | Oppenheimer | Leland Gershell | — | Downgrade | Outperform → Perform | Get Alert |
| 10/11/2023 | Buy Now | -0.17% | RBC Capital | Luca Issi | $270 → $235 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | 67.8% | HC Wainwright & Co. | Patrick Trucchio | $405 → $395 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | -25.66% | Morgan Stanley | Michael Ulz | $210 → $175 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | -0.59% | BMO Capital | Kostas Biliouris | $250 → $234 | Maintains | Outperform | Get Alert |
| 10/10/2023 | Buy Now | -1.02% | Citigroup | David Lebovitz | $266 → $233 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | -15.04% | Needham | Joseph Stringer | $240 → $200 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | -11.64% | Raymond James | Gary Nachman | → $208 | Initiates | → Outperform | Get Alert |
| 09/18/2023 | Buy Now | 72.05% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 1.95% | Stifel | Paul Matteis | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | -19.29% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 09/14/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2023 | Buy Now | -19.29% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 08/08/2023 | Buy Now | 6.2% | Chardan Capital | Keay Nakae | → $250 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 72.05% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | -10.79% | Morgan Stanley | Michael Ulz | $210 → $210 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 13% | Citigroup | David Lebovitz | $265 → $266 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 14.7% | RBC Capital | Luca Issi | $275 → $270 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 72.05% | HC Wainwright & Co. | Patrick Trucchio | $415 → $405 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | -15.04% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 07/12/2023 | Buy Now | -15.04% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/23/2023 | Buy Now | -15.04% | Cantor Fitzgerald | Olivia Brayer | $200 → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/22/2023 | Buy Now | -15.04% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 05/31/2023 | Buy Now | 16.82% | RBC Capital | Luca Issi | → $275 | Reiterates | Outperform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | 6.2% | BMO Capital | Kostas Biliouris | $200 → $250 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 76.3% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Reiterates | → Buy | Get Alert |
| 04/26/2023 | Buy Now | -6.54% | SMBC Nikko | David Hoang | → $220 | Initiates | → Neutral | Get Alert |
| 04/04/2023 | Buy Now | -10.79% | Morgan Stanley | Michael Ulz | $205 → $210 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | 3.23% | Bernstein | William Pickering | → $243 | Initiates | → Outperform | Get Alert |
| 03/03/2023 | Buy Now | -16.74% | JP Morgan | Jessica Fung | $200 → $196 | Maintains | Neutral | Get Alert |
| 03/03/2023 | Buy Now | 76.3% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 23.62% | Canaccord Genuity | Whitney Ijem | $310 → $291 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | -12.91% | Morgan Stanley | Michael Ulz | $210 → $205 | Maintains | Equal-Weight | Get Alert |
| 02/24/2023 | Buy Now | 12.57% | Citigroup | David Lebovitz | $270 → $265 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 5.78% | Oppenheimer | Leland Gershell | $256 → $249 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 6.2% | Chardan Capital | Keay Nakae | → $250 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 29.14% | EF Hutton | Michael King | → $304 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 1.95% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 29.14% | EF Hutton | Michael King | → $304 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY) stock?
The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by Cantor Fitzgerald on July 22, 2024. The analyst firm set a price target for $220.00 expecting ALNY to fall to within 12 months (a possible -6.54% downside). 78 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by Cantor Fitzgerald, and Alnylam Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on May 5, 2023 when BMO Capital raised their price target to $250. BMO Capital previously had a market perform for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on February 16, 2024 when Goldman Sachs changed their price target from $230 to $173 for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $150.00 to $220.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $235.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.